SRSF2 mutation cooperates with ASXL1 truncated alteration to accelerate leukemogenesis
Open Access
- 28 November 2023
- journal article
- letter
- Published by Springer Nature in Leukemia
- Vol. 38 (2) , 408-411
Abstract
No abstract availableKeywords
Funding Information
- Foundation for the National Institutes of Health (HL149318, CA172408, HL145883, HL158081, CA172408, HL145883, R01HL128239, R01HL128239)
This publication has 12 references indexed in Scilit:
- Acute Myeloid Leukemia with Co‐mutated ASXL1 and SRSF2 Exhibits Monocytic Differentiation and has a Mutational Profile Overlapping with Chronic Myelomonocytic LeukemiaHemaSphere, 2019
- Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignanciesBlood, 2018
- Genomic Classification and Prognosis in Acute Myeloid LeukemiaNew England Journal of Medicine, 2016
- The genomic landscape of juvenile myelomonocytic leukemiaNature Genetics, 2015
- Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndromeBlood Cancer Journal, 2014
- Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromesBlood, 2012
- Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasmsGenes, Chromosomes and Cancer, 2012
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid LeukemiaNew England Journal of Medicine, 2012
- Prognostic Significance ofASXL1Mutations in Patients With Myelodysplastic SyndromesJournal of Clinical Oncology, 2011
- ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemiaBritish Journal of Haematology, 2010